Path integral evaluation of Dbrane amplitudes

We extend Polchinski's evaluation of the measure for the one-loop closed string path integral to open string tree amplitudes with boundaries and crosscaps embedded in Dbranes. We explain how the nonabelian limit of near-coincident Dbranes emerges in the path integral formalism. We give a careful path integral derivation of the cylinder amplitude including the modulus dependence of the volume of the conformal Killing group.Comment: Extended version replacing hep-th/9903184, includes discussion of nonabelian limit, Latex, 10 page

Quantum algebras in phenomenological description of particle properties

Quantum and q-deformed algebras find their application not only in mathematical physics and field theoretical context, but also in phenomenology of particle properties. We describe (i) the use of quantum algebras U_q(su_n) corresponding to Lie algebras of the groups SU(n), taken for flavor symmetries of hadrons, in deriving new high-accuracy hadron mass sum rules, and (ii) the use of (multimode) q-oscillator algebras along with q-Bose gas picture in modelling the properties of the intercept \lambda of two-pion (two-kaon) correlations in heavy-ion collisions, as \lambda shows sizable observed deviation from the expected Bose-Einstein type behavior. The deformation parameter q is in case (i) argued and in case (ii) conjectured to be connected with the Cabibbo angle \theta_C.Comment: Latex, espcrc2.sty, 8 pages, 1 figure; v4: eq.(19) corrected. Based on talk given at the D.V.Volkov Memorial Conference (25-29 July, 2000, Kharkov, Ukraine

Non-Abelian Vortices, Super-Yang-Mills Theory and Spin(7)-Instantons

We consider a complex vector bundle E endowed with a connection A over the eight-dimensional manifold R^2 x G/H, where G/H = SU(3)/U(1)xU(1) is a homogeneous space provided with a never integrable almost complex structure and a family of SU(3)-structures. We establish an equivalence between G-invariant solutions A of the Spin(7)-instanton equations on R^2 x G/H and general solutions of non-Abelian coupled vortex equations on R^2. These vortices are BPS solitons in a d=4 gauge theory obtained from N=1 supersymmetric Yang-Mills theory in ten dimensions compactified on the coset space G/H with an SU(3)-structure. The novelty of the obtained vortex equations lies in the fact that Higgs fields, defining morphisms of vector bundles over R^2, are not holomorphic in the generic case. Finally, we introduce BPS vortex equations in N=4 super Yang-Mills theory and show that they have the same feature.Comment: 14 pages; v2: typos fixed, published versio

Renormalization group flows and continual Lie algebras

We study the renormalization group flows of two-dimensional metrics in sigma models and demonstrate that they provide a continual analogue of the Toda field equations based on the infinite dimensional algebra G(d/dt;1). The resulting Toda field equation is a non-linear generalization of the heat equation, which is integrable in target space and shares the same dissipative properties in time. We provide the general solution of the renormalization group flows in terms of free fields, via Backlund transformations, and present some simple examples that illustrate the validity of their formal power series expansion in terms of algebraic data. We study in detail the sausage model that arises as geometric deformation of the O(3) sigma model, and give a new interpretation to its ultra-violet limit by gluing together two copies of Witten's two-dimensional black hole in the asymptotic region. We also provide some new solutions that describe the renormalization group flow of negatively curved spaces in different patches, which look like a cane in the infra-red region. Finally, we revisit the transition of a flat cone C/Z_n to the plane, as another special solution, and note that tachyon condensation in closed string theory exhibits a hidden relation to the infinite dimensional algebra G(d/dt;1) in the regime of gravity. Its exponential growth holds the key for the construction of conserved currents and their systematic interpretation in string theory, but they still remain unknown.Comment: latex, 73pp including 14 eps fig

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Parcelamento e largura da faixa de aplicação da uréia na recuperação do nitrogênio pela planta de milho Splitting and width of strip urea applications and the recovery of nitrogen by maize plants

Com o objetivo de estudar o parcelamento e a largura da faixa de aplicação como meios para aumentar a recuperação pelo milho do nitrogênio da uréia aplicada em superfície, foi conduzido no ano agrícola 93/94, em um Latossolo Vermelho Escuro, em condições de campo, um experimento delineado em blocos ao acaso, com cinco repetições. Sete tratamentos foram utilizados: testemunha (sem N em cobertura); aplicação de N parcelada (50 kg ha-1 de N aos 38 dias após semeadura - d.a.s e 50 kg ha-1 de N aos 60 d.a.s.) para faixas de 10, 20 e 40 cm; aplicação de N (100 kg ha-1 de N aos 38 d.a.s.) para faixas de 10 e 40 cm e, aplicação de N parcelada (50 kg de N/ha aos 38 d.a.s. e 50 kg ha-1 de N aos 60 d.a.s.) para faixa de 20 cm de largura, neste caso, uréia granulada. A aplicação de uréia parcelada em cobertura, em faixas de 10, 20 e 40 cm de largura, não afetaram a massa de matéria seca, o conteúdo, a quantidade e a recuperação do N pela planta de milho. A recuperação de N pela planta de milho foi maior para a aplicação de 220 kg ha-1 de uréia em uma única aplicação em faixas de 10cm de largura em relação a de 40 cm. O parcelamento da uréia aumentou os valores de massa seca, conteúdo, quantidade e recuperação do N na planta de milho em relação a aplicação em uma única vez.<br>In order to evaluate the nitrogen recovery by maize, following a surface application of urea, a trial was carried out during 1993/94 under field conditions, on a dark red latosol (oxisol). A randomized complete block statistical design was used, with seven treatments and five replications. The seven treatments were: control (no N); three split N applications (50 kg N ha-1 urea at 38 and 60 days after sowing) using 10, 20 or 40 cm width strips; two single N applications (100 kg N ha-1 urea at 38 days after sowing) using 10 or 40 cm width strips; and split N applications (50 kg N ha-1 urea at 38 and 60 days after sowing) using a 20 cm width strip (granular urea). The top dressing that was applied at two growth stages in 10, 20 or 40 cm width strips did not affect dry matter production, content, amount and recovery of N in the corn plant. Only when one urea application was made, the recovery of N from the corn plant was larger for the 10 cm of width in relation to 40 cm. The split application increased significantly dry matter production, content, amount and recovery of N in the corn plant in one single application